Skip to content
TESCT — Trans European Stem Cell Therapy Society
Micrograph of a stem cell colony

About the society

A society built to close
the translation gap.

TESCT is a European expert forum for regenerative medicine, founded in 2005 and still run by the clinicians and scientists who use it.

Delegates at a European committee meeting on stem cell therapy

Milestone meetings have been held at the Royal Academy of Medicine in London, the University of Dakar, the University of Ljubljana and the European Commission in Brussels.

Our story

Founded to make sure good science actually reaches patients.

The Trans European Stem Cell Therapy Society (TESCT) was founded in 2005 by Dr. Marco Traub PhD in Switzerland to encourage the speedy transfer of stem cell technology from laboratory translation to clinical practice, with the focus on the patient and the improvement of the quality of life.

Together with Rosie Graham from London the TESCT Society was formed to an expert forum and arranged milestone meetings at the Royal Academy of Medicine London and the University of Dakar and University of Ljubljana and the European Commission, Brussels.

Stakeholders from science and politics joined over the years — Julia Polak, Marco Cappato and Mary Baker among many more.

Milestone meetings

  1. 01Berne, SwitzerlandDr. Marco Traub founds the Trans European Stem Cell Therapy Consortium, with Rosie Graham in London, as an expert forum for translational stem cell medicine.
  2. 02Royal Academy of Medicine, LondonThe society's first milestone meeting opens the debate between stem cell biology, regulation and clinical practice.
  3. 03University of DakarAn early trans-continental meeting that extended the society's scope beyond Europe, in line with its trans-European name.
  4. 04University of LjubljanaA collaboration with the National Institute of Biology that continues to underpin the society's work-meeting programme.
  5. 05European Commission, BrusselsEngagement with the institutions that shape cell therapy regulation, Horizon 2020 and the Innovative Medicines Initiative.

Our vision

Five convictions about where regenerative medicine should go.

The society's vision statement has not been rewritten for this site. It is the position TESCT has argued for since its founding — science first, patients first, and prevention alongside treatment.

  • 01

    Scientific and technological advances in medical diagnostics and therapeutics.

  • 02

    Implementation of validated natural based drugs in existing therapeutic regimens.

  • 03

    Focus on the greater social impact of disease on the society in total.

  • 04

    Focus and emphasis on disease prevention, e.g. through a healthier lifestyle.

  • 05

    Redefining the role of pharmaceutical companies within the health care system and their impact on the translational research sector at large.

Philosophy

The patient is the endpoint.

The Trans European Stem Cell Therapy Society (TESCT) was founded in 2005 by Dr. Marco Traub PhD in Switzerland to encourage the speedy transfer of stem cell technology from laboratory translation to clinical practice, with the focus on the patient and the improvement of the quality of life.

The society was deliberately built as a mixed forum. Clinicians and laboratory scientists sit with regulators, ethicists, patient organisations and industry — because each of them holds a piece of what "translation" actually requires.

Paper figures holding hands, representing patient organisations

22

Members and advisers across nine countries

10

International work meetings since 2005

Specific aims

What the society commits to.

Five aims, agreed by the membership and unchanged in substance since the founding charter.

  1. 01

    Scientific and technological advances in medical diagnostics and therapeutics.

  2. 02

    Implementation of validated natural based drugs in existing therapeutic regimens.

  3. 03

    Focus on the greater social impact of disease on society in total.

  4. 04

    Focus and emphasis on disease prevention, e.g. through a healthier lifestyle.

  5. 05

    Redefining the role of pharma companies within the health care system and their impact on the translational research sector at large.

Founders

Who started it.

The society was formed by two people who had seen how much promising work never reached a clinic.

Portrait of Dr. Marco Traub

Dr. Marco Traub

CEO & Founder

Founder and chair of the TESCT consortium, an EU Commission expert in FP7, Horizon 2020 and the Innovative Medicines Initiative, and a specialist in stem cell isolation, expansion and banking.

Read the profile
Portrait of Rosie Graham

Rosie Graham

Co-founder, TESCT Society

Co-founded the TESCT Society with Dr. Marco Traub in 2005, helping to turn it into an expert forum convening science, medicine, policy and patients across Europe.

Read the profile

Working on translation? The society should know about it.

Write to the secretariat in Berne or London.

Contact TESCT